Sample Report

Cell Therapy Manufacturing Global Market Report, First Edition: 2023-2028

This report provides an overview of the cell therapy manufacturing market from 2023 to 2028. The cell therapy manufacturing market, as defined in this report, is comprised of revenue from instruments, consumables, and software sold to academic, clinical, biopharma, CDMO and CRO customers, along with service revenues generated by CDMOs and CROs.

See more details below.

 

 

Complete this form to receive a copy of the sample report.

Segmentations Covered in Market Analysis:

Customer:
  • Large Biopharma
  • Small Biopharma
  • Academic
  • CRO
  • CDMO
Products & Services:
  • Consumables
  • Instruments
  • Software
  • Process Development
  • Analytical Development
  • GMP Manufacturing
Stage of Development:
  • Basic Discover
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Commercial (approved)
Therapeutic Area:
  • Oncology
  • Neurology
  • Immunological
  • Rare Disease
  • Other
Cell Type:
  • CAR-T
  • TCR-T
  • NK / NKT
  • Stem Cell
  • Other (e.g., TIL, CAR-M, etc.)
Method:
  • Autologous
  • Allogeneic
Geography:
  • United States
  • Europe
  • APAC
  • Rest of World (RoW)

Companies Profiled in the Report:
  • Bio-Techne
  • Catalent
  • Charles River
  • Corning
  • Creative Bioarray
  • Cytiva
  • Fujifilm Diosynth Biotechnologies
  • Lonza
  • Maxcyte
  • Millipore Sigma
  • Miltenyi Biotec
  • Revvity
  • Samsung Biologics
  • Sartorius
  • STEMCELL Technologies
  • ThermoFisher
  • Wilson Wolf
  • WuXi AppTec

Technologies and Revenues Included:

  • Consumable, instrument, and software revenues associated with the purchase of raw materials, cell manufacturing platforms or tools, or software used to run the platforms / tools, from basic discovery to commercial manufacturing
  • Service revenues associated with the development of a cell therapy product (e.g., process development, analytical development, or GMP manufacturing), typically offered by CROs and CDMOs
  • All cell types under investigation for use as a cell therapy product including CAR-T, TCR-T, NK / NKT, stem cells, TILs, and myeloid cells
  • All steps in the cell manufacturing process, including cell isolation, genetic modification, cell expansion, cryopreservation, and fill / finish
  • Global sales of products and services to academic, clinical, biotech / pharmaceutical companies, CRO, and CDMO customers

Technologies and Revenues Excluded:

  • Instrumentation, assays, and reagents used upstream of cell manufacturing for plasmid and viral vector production
  • Spend downstream of cell therapy manufacturing (e.g., administration of therapy to patients)
  • Extracellular vesicle-based therapeutics

©2024 DeciBio. All rights reserved.